BPC-157 + Thymosin Alpha-1: the stack guide

BPC-157 plus Thymosin Alpha-1 pairs a gut-healing peptide with an immune-modulating peptide. It's frequently asked about by users dealing with post-viral inflammation, leaky-gut complaints, or autoimmune flares who want both a tissue-repair agent and an immune-recalibrating one.

BPC-157 250–500 mcg subcutaneous daily, plus Thymosin Alpha-1 1.6 mg subcutaneous twice weekly (standard clinical cadence for Tα1). Cycles typically run 8–12 weeks. BPC-157 can be continued longer; Tα1 is often cycled with a break after 12 weeks.

Many users co-administer GHRH + GHRP pairs (like CJC-1295 + Ipamorelin) in a single syringe to reduce injections, since both are stable in bacteriostatic water for short periods. For other pairs, draw and inject separately to minimize compatibility risk and to attribute any reaction to the correct compound.

Tα1 can produce transient flu-like symptoms and injection-site erythema at the start of therapy — this usually settles within 1–2 weeks. Do not use during active immunosuppression for transplant or autoimmune protocols without oncology/rheumatology input — Tα1's immune-activating effects can conflict with those regimens. BPC-157 is research-use only in the US.

Most user-reported cycles run 4–12 weeks depending on the goal. GH-axis stacks are typically cycled with a break of 4 weeks or more between blocks to preserve receptor sensitivity. Soft-tissue stacks are usually run continuously until the injury resolves.